{"id":154738,"date":"2018-02-28T07:52:10","date_gmt":"2018-02-28T12:52:10","guid":{"rendered":"https:\/\/canadianinquirer.net\/v1\/?p=154738"},"modified":"2018-02-28T08:06:09","modified_gmt":"2018-02-28T13:06:09","slug":"sanofi-dismisses-hiding-risks-of-dengvaxia-from-ph","status":"publish","type":"post","link":"https:\/\/canadianinquirer.net\/v1\/2018\/02\/28\/sanofi-dismisses-hiding-risks-of-dengvaxia-from-ph\/","title":{"rendered":"Sanofi dismisses hiding risks of Dengvaxia from PH"},"content":{"rendered":"<figure id=\"attachment_153454\" aria-describedby=\"caption-attachment-153454\" style=\"width: 960px\" class=\"wp-caption alignnone\"><a href=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2018\/02\/Parents-of-vaccinated-children.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-153454\" src=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2018\/02\/Parents-of-vaccinated-children.jpg\" alt=\"FILE: French pharmaceutical giant Sanofi Pasteur on Wednesday dismissed accusations that it concealed risk of its anti-dengue vaccine Dengvaxia from the Philippines in 2015.(Photo: Department of Health (Philippines)\/Facebook)\" width=\"960\" height=\"640\" srcset=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2018\/02\/Parents-of-vaccinated-children.jpg 960w, https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2018\/02\/Parents-of-vaccinated-children-300x200.jpg 300w, https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2018\/02\/Parents-of-vaccinated-children-768x512.jpg 768w\" sizes=\"auto, (max-width: 960px) 100vw, 960px\" \/><\/a><figcaption id=\"caption-attachment-153454\" class=\"wp-caption-text\">FILE: French pharmaceutical giant Sanofi Pasteur on Wednesday dismissed accusations that it concealed risk of its anti-dengue vaccine Dengvaxia from the Philippines in 2015. (<a href=\"https:\/\/www.facebook.com\/OfficialDOHgov\/photos\/pcb.1870300092981234\/1870299989647911\/?type=3&amp;amp;theater\">Photo<\/a>: <a href=\"https:\/\/www.facebook.com\/OfficialDOHgov\/\">Department of Health (Philippines)\/Facebook<\/a>)<\/figcaption><\/figure>\n<p>French pharmaceutical giant Sanofi Pasteur on Wednesday dismissed accusations that it concealed risk of its anti-dengue vaccine Dengvaxia from the Philippines in 2015.<\/p>\n<p>\u201cSanofi Pasteur would like to address the inaccurate information regarding the transparency of data and findings related to Dengvaxia.\u00a0 All our vaccines undergo extensive clinical investigations and their efficacy, safety and public health impact is continuously followed up post license,\u201d Sanofi said in a statement.<\/p>\n<p>The French firm defended that there was no information about the risks of the vaccine until November 2017.<\/p>\n<p>\u201cFor the dengue vaccine, from the time of the sale, until November 2017, we had no information or data with regards to the serostatus of the vaccinees showing a different product profile in the population of nine-years-old and above,\u201d it said.<\/p>\n<p>Sanofi added that they immediately disclosed its findings, based on a six-year analysis of clinical data, on November 29 last year.<\/p>\n<p>\u201cWe learnt of the different product profile of the dengue vaccine for those with or without a previous dengue infection in November 2017 and Sanofi Pasteur has shared the new data in full transparency with national health authorities countries where the vaccine is approved or where it is being considered for regulatory approval,\u201d it added.<\/p>\n<p>During a congressional hearing into the now-suspended dengue immunization program, Food and Drug Administration (FDA) Director-General Nela Charade Puno claimed that the drug maker was well-aware of the risks of Dengvaxia, however, it did not inform the Philippine government.<\/p>\n<p>According to Puno, the DFA\u2019s special task force assessed the papers Sanofi submitted to Singapore that allowed the commercial sale of Dengvaxia in their country in October 2016.<\/p>\n<p>Puno added that the French company could have been aware of the possible risks of Dengvaxia as it already informed Singapore that it will cause severe dengue if administered to an individual who has not been infected by the mosquito-borne disease.<\/p>\n<p>\u201cIn their publication, they already announced it\u2019s not to be used for patients who haven\u2019t had dengue [before vaccination],&#8221; Puno said.<\/p>\n<p>&#8220;So <em>ibig sabihin, alam nila. Dapat<\/em> [noong] December 22, 2015, <em>alam na nila at dapat sinabi na nila sa Pilipinas na hindi ito puwede sa mga batang &#8216;di pa nagkakaroon ng<\/em> dengue (It means that they know it already. On December 22, 2015, they know it already and should have informed the Philippines that the vaccine cannot be given to children who haven\u2019t had dengue),&#8221; she added.<\/p>\n<p>It was also on December 22 when the DFA permitted Sanofi to commercially sell Dengvaxia in the country. Sanofi only issued the warning on its vaccine in November last year.<\/p>\n<p>Due to this admission, the government\u2019s immunization program was halted. This program, launched by former Health Secretary Janette Garin in April 2016, vaccinated at least 833,000 public school pupils.<\/p>\n<p>The Department of Health (DOH) requested Sanofi to fully reimburse the fund used in purchasing the vials and provide indemnification fund to those who received the vaccine.<\/p>\n<p>The drug maker, however, rejected this request saying that refunding the used doses of Dengvaxia would only mean that the vaccine is ineffective, \u201cwhich is not the case.\u201d It added that there is also \u201cno known circumstance requiring indemnification.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>French pharmaceutical giant Sanofi Pasteur on Wednesday dismissed accusations that it concealed risk of its anti-dengue vaccine Dengvaxia from the &hellip;<\/p>\n","protected":false},"author":33,"featured_media":153454,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1145,16,95],"tags":[36849,27812,36623],"class_list":["post-154738","post","type-post","status-publish","format-standard","has-post-thumbnail","category-headline","category-news","category-news-ph","tag-dengvaxia","tag-risks","tag-sanofi-pasteur","mauthors-joanna-belle-deala","mauthors-philippine-canadian-inquirer"],"_links":{"self":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/154738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/comments?post=154738"}],"version-history":[{"count":0,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/154738\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media\/153454"}],"wp:attachment":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media?parent=154738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/categories?post=154738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/tags?post=154738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}